Analysis of health-related quality of life (HR-QOL) data from the GiACTA trial, in which 251 patients with giant cell arteritis (GCA) were treated with either tocilizumab or placebo in addition to a tapered dose of prednisone, showed improvements in overall HR-QOL for patients treated with tocilizumab plus prednisone compared with those treated with placebo plus prednisone. Clinically meaningful differences were reported for 36-Item Short-Form Health Survey Mental Component Summary scores (P = 0.0012) and for Patient Global Assessment scores (P = 0.0029) in those receiving tocilizumab.
References
Original article
Strand, V. et al. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res. Ther. 21, 64 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Tocilizumab improves quality of life in GCA. Nat Rev Rheumatol 15, 188 (2019). https://doi.org/10.1038/s41584-019-0197-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0197-7
